A Placebo-Controlled Pilot Study of the Novel Opioid Receptor Antagonist ALKS-33 in Binge Eating Disorder
Volume 46, Issue 3
Total CE Credit Hours: 1
Course Info URL: http://www.ce-credit.com/courses/102000
About the Course:
To assess preliminarily the effectiveness of a novel opioid antagonist, ALKS-33, in binge eating disorder (BED).
Wiley Interscience Journal, International Journal of Eating Disorders
Susan L. McElroy, MD; Anna I. Guerdjikova, PhD, LISW; Thomas J. Blom, MS; Scott J. Crow, MD; Asli Memisoglu, PhD; Bernard L. Silverman, MD; Elliot W. Ehrich, MD
This course is recommended for professionals who seek knowledge about the pharmacotherapy of binge eating disorder.
Describe the role endogenous opioids may play in binge eating behavior.
Describe the rational for use of opioid antagonists in BED.
Explain that in a small phase II, proof of concept study in 62 outpatients with BED, the novel opioid antagonist ALK-33 was not superior to placebo on any measure of eating pathology or body weight.
All exam questions for the course are visible on this page for members of CE-credit.com.
If you're already a member, please login to see the exam questions for this and all other courses.